A key step towards reducing the burden of central nervous system (CNS) disorders is the identification of disease-specific biomarkers that can help predict, monitor, and guide treatment development.

The central nervous system (CNS) critically depends on the integrity of oligodendrocytes, specialised glial cells responsible for the formation and maintenance of myelin sheaths. Myelin not only ...

Racism, discrimination, and social determinants of health have contributed to clear disparities in health and health outcomes, particularly in central nervous system (CNS) disorders. Recognizing the ...

Guanosine, a purine nucleoside, has emerged as a potent modulator within the central nervous system (CNS), contributing to neuroprotection through a diverse array of mechanisms. It plays a critical ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

New AI-Driven Planning Platform Designed to Unlock a New Class of Disease-Modifying Therapies for CNS Disorders MUNICH & REDWOOD CITY, Calif.--(BUSIN ...

This color-coded graphic shows different populations of cells in the mouse brain, each one targeted by one of the genetic tools developed by scientists at the Allen Institute and other institutions.

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal ...

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday ...

Jupiter’s strategy combines clinical development with active commercial revenue generation. The Company views direct engagement with the investment community as an ongoing part of its philosophy to ...